Pegaldesleukin

Drug Profile

Pegaldesleukin

Alternative Names: PEG interleukin-2; Proleukin-PEG™

Latest Information Update: 23 Feb 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Research Corporation Technologies
  • Developer Chiron Corporation; Eurocetus; Nonindustrial source; Research Corporation Technologies
  • Class Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer metastases; Head and neck cancer; HIV-1 infections; Prostate cancer

Most Recent Events

  • 23 Feb 2004 Discontinued - Clinical-Phase-Unknown for HIV-1 infections in France (IV)
  • 23 Feb 2004 Discontinued - Phase-I for Head and neck cancer in Netherlands (Intratumoural)
  • 23 Feb 2004 Discontinued - Phase-II for Cancer metastases in Netherlands (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top